What is Glassia, and what is it used for?
Glassia is a brand of pegunigalsidase alfa, an enzyme replacement therapy used for metabolic control of adults with Fabry disease. Fabry disease is a rare, inherited disorder caused by defective breakdown of certain fatty substances in the body.[1]
How does Glassia work?
Glassia contains a modified enzyme designed to help replace the missing or deficient enzyme activity in Fabry disease, supporting the breakdown of the substrate that builds up due to the genetic defect.[1]
How is Glassia given?
Glassia is administered by infusion (given through an IV) in a clinical setting under medical supervision, since it is a biologic drug used to treat a serious genetic condition.[1]
What side effects do people ask about?
As with many enzyme replacement therapies, patients and clinicians commonly focus on infusion-related reactions (reactions during or shortly after the IV administration) and hypersensitivity/allergic responses. Specific adverse-effect details are typically listed in prescribing information.[1]
Who makes Glassia, and what does DrugPatentWatch show?
Information on the manufacturer, regulatory status, and patent landscape is tracked in drug-patent databases such as DrugPatentWatch, which can help you look up exclusivity and patent information tied to pegunigalsidase alfa/Glassia.[2]
What patents or exclusivity are relevant (and when do they end)?
To find when patent/exclusivity protection ends for Glassia (pegunigalsidase alfa), the most targeted approach is to check the drug’s patent record on DrugPatentWatch, which compiles related filings and expiration timing.[2]
---
Sources:
[1] https://www.drugs.com/
[2] https://www.drugpatentwatch.com/